EA202190429A1 - Биодоступные пероральные дозированные формы - Google Patents

Биодоступные пероральные дозированные формы

Info

Publication number
EA202190429A1
EA202190429A1 EA202190429A EA202190429A EA202190429A1 EA 202190429 A1 EA202190429 A1 EA 202190429A1 EA 202190429 A EA202190429 A EA 202190429A EA 202190429 A EA202190429 A EA 202190429A EA 202190429 A1 EA202190429 A1 EA 202190429A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dosage forms
oral dosage
bioavailable oral
bioavailable
pharmaceutical compositions
Prior art date
Application number
EA202190429A
Other languages
English (en)
Russian (ru)
Inventor
Мандар В. Дали
Акм Насир Уддин
Original Assignee
ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67766269&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202190429(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ПиТиСи ТЕРАПЬЮТИКС, ИНК. filed Critical ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Publication of EA202190429A1 publication Critical patent/EA202190429A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA202190429A 2018-08-03 2019-08-02 Биодоступные пероральные дозированные формы EA202190429A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862714182P 2018-08-03 2018-08-03
PCT/US2019/044853 WO2020028778A1 (en) 2018-08-03 2019-08-02 Bioavailable oral dosage forms

Publications (1)

Publication Number Publication Date
EA202190429A1 true EA202190429A1 (ru) 2021-06-15

Family

ID=67766269

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190429A EA202190429A1 (ru) 2018-08-03 2019-08-02 Биодоступные пероральные дозированные формы

Country Status (23)

Country Link
US (1) US20210205225A1 (cg-RX-API-DMAC7.html)
EP (1) EP3829544A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021532193A (cg-RX-API-DMAC7.html)
KR (1) KR20210041589A (cg-RX-API-DMAC7.html)
CN (1) CN112752570A (cg-RX-API-DMAC7.html)
AR (1) AR115913A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019316036A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021001859A2 (cg-RX-API-DMAC7.html)
CA (1) CA3107737A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000271A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021001979A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210093A (cg-RX-API-DMAC7.html)
EA (1) EA202190429A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP21011795A (cg-RX-API-DMAC7.html)
IL (1) IL280471A (cg-RX-API-DMAC7.html)
MX (1) MX2021001364A (cg-RX-API-DMAC7.html)
NI (1) NI202100006A (cg-RX-API-DMAC7.html)
PE (1) PE20211410A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550237A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100984VA (cg-RX-API-DMAC7.html)
TN (1) TN2021000021A1 (cg-RX-API-DMAC7.html)
TW (1) TW202019414A (cg-RX-API-DMAC7.html)
WO (1) WO2020028778A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE052510T2 (hu) 2009-05-27 2021-05-28 Ptc Therapeutics Inc Módszerek a rák és a nem daganatos állapotok kezelésére
US11458126B2 (en) 2017-08-01 2022-10-04 Ptc Therapeutics, Inc. DHODH inhibitor for use in treating hematologic cancers
CN112028888B (zh) * 2020-09-11 2021-08-20 中国药科大学 一种化合物及其制备方法和用途
WO2023130070A2 (en) 2021-12-31 2023-07-06 Ptc Therapeutics, Inc. Carboline compounds and use thereof
US20220151938A1 (en) * 2022-01-28 2022-05-19 Ptc Therapeutics, Inc. Tablet for use in treating huntington's disease and method of making the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050249799A1 (en) 2004-03-03 2005-11-10 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US7601840B2 (en) 2004-03-15 2009-10-13 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US20100158858A1 (en) 2007-04-13 2010-06-24 Liangxian Cao Administration of carboline derivatives useful in the treatment of cancer and other diseases
HRP20191104T1 (hr) 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2010138706A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating breast cancer
HUE052510T2 (hu) 2009-05-27 2021-05-28 Ptc Therapeutics Inc Módszerek a rák és a nem daganatos állapotok kezelésére
US20180344646A1 (en) * 2015-11-25 2018-12-06 Patheon Development Services Inc. Amorphous dispersion granules and oral dosage forms

Also Published As

Publication number Publication date
KR20210041589A (ko) 2021-04-15
TW202019414A (zh) 2020-06-01
PE20211410A1 (es) 2021-08-02
JP2021532193A (ja) 2021-11-25
SG11202100984VA (en) 2021-02-25
WO2020028778A1 (en) 2020-02-06
CN112752570A (zh) 2021-05-04
IL280471A (en) 2021-03-25
PH12021550237A1 (en) 2021-10-11
TN2021000021A1 (en) 2022-10-03
CA3107737A1 (en) 2020-02-06
US20210205225A1 (en) 2021-07-08
EP3829544A1 (en) 2021-06-09
CO2021001979A2 (es) 2021-03-08
MX2021001364A (es) 2021-04-13
CR20210093A (es) 2021-05-28
CL2021000271A1 (es) 2021-08-20
AR115913A1 (es) 2021-03-10
NI202100006A (es) 2021-05-21
BR112021001859A2 (pt) 2021-04-27
ECSP21011795A (es) 2021-03-31
AU2019316036A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
CY1124548T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
EA201890654A1 (ru) Терапевтические композиции для лечения вируса иммунодефицита человека
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
CY1124532T1 (el) Δοσολογικα σχηματα για συζευγματα φαρμακου-αντισωματος αντι-tf
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
EA201992116A1 (ru) Фармацевтические составы флороглюцинола и триметилфлороглюцинола
EA201792591A1 (ru) Фармацевтические препараты
PH12021550237A1 (en) Bioavailable oral dosage forms.
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA202090542A1 (ru) Высококонцентрированные лекарственные формы придопидина
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA201892837A1 (ru) Физиологически сбалансированные составы для инъекций, включающие фоснетупитант
EA201792401A1 (ru) Композиции для очищения толстого кишечника и лечения желудочно-кишечных расстройств
EA202090666A1 (ru) Применение содержащей бензоат композиции для лечения глициновой энцефалопатии
EA201600486A1 (ru) Фармацевтические композиции, включающие антикоагулянт n-(5-хлорпиридин-2-ил)-2-({4-[этанимидоил(метил)амино]бензоил}амино)-5-метилбензамид
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
EA201892842A1 (ru) Фармацевтические композиции, включающие сафинамид
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
EA201890477A1 (ru) Инкапсулированная композиция финголимода
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
EA202190626A3 (ru) Комбинация тразодона и габапентина для лечения боли